Document is current
Any future updates will be listed below
-
Authors
Kamiya, Mari
Mizoguchi, Fumitaka
Kawahata, Kimito
Wang, Dengli
Nishibori, Masahiro
Day, Jessica http://orcid.org/0000-0001-8528-4361
Louis, Cynthia http://orcid.org/0000-0001-8382-6358
Wicks, Ian P. http://orcid.org/0000-0001-7050-6822
Kohsaka, Hitoshi
Yasuda, Shinsuke http://orcid.org/0000-0001-6171-2077
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP19K23839, JP19K08903, JP15H04863)
Bristol-Myers Squibb (41907503)
Department of Health | National Health and Medical Research Council (1113577)
- License Information
-
More Information
Article History
Received: 25 July 2020
Accepted: 16 December 2021
First Online: 10 January 2022
Competing interests
: F.M. received research funding from AbbVie, Astellas Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Company, Eisai, Eli Lilly and Company, ImmunoForge, Japan Blood Products Organization, Mitsubishi Tanabe Pharma, Novartis Pharma Japan, Ono Pharmaceutical, Otsuka Pharmaceutical Factory, Pfizer, Sanofi, Takeda Pharmaceutical Company and Teijin, consulting fees from Asahi Kasei Pharma and ImmunoForge, and speaking fees from AbbVie, Asahi Kasei Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical, Eizai, Eli Lilly and Company, Glaxo Smith Kline, Ono Pharmaceutical, and Pfizer. H.K. received consulting fees from CSL Behring and Japan Blood Products Organization. S.Y. received research funding from Abbvie, Asahi Kasei Pharma, Chugai Pharmaceutical, CSL Behring, Eisai, ImmunoForge, Mitsubishi Tanabe Pharma, and Ono pharmaceutical, speaking fees from Abbvie, Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Eli Lilly, GlaxoSmithKline, Mitsubishi Tanabe Pharma, Ono pharmaceutical, and Pfizer. I.P.W. received consulting fees from CSL Limited. M.K., K.K., D.W., M.N., J.D., and C.L. declare that no conflict of interest exists.
